Literature DB >> 8566106

Modulation of glutamate release by a kappa-opioid receptor agonist in rodent and primate striatum.

M P Hill1, J M Brotchie.   

Abstract

The influence of the kappa-opioid receptor agonist, enadoline, on endogenous glutamate release was investigated in rat and marmoset striatal synaptosomes. Enadoline decreased 4-aminopyridine (2 mM)-stimulated glutamate release (rat: IC50 approximately 8.7 microM, marmoset: IC50 approximately 2.9 microM). The effect of enadoline was reversed by nor-binaltorphimine (5 microM). These data indicate that, in the striatum of the rat and marmoset, kappa-opioid receptor agonists can modulate glutamate release. These findings may have implications for the treatment of Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8566106     DOI: 10.1016/0014-2999(95)00385-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease.

Authors:  B Henry; J M Brotchie
Journal:  Drugs Aging       Date:  1996-09       Impact factor: 3.923

2.  Control of glutamate release by calcium channels and kappa-opioid receptors in rodent and primate striatum.

Authors:  M P Hill; J M Brotchie
Journal:  Br J Pharmacol       Date:  1999-05       Impact factor: 8.739

3.  Nalfurafine, the kappa opioid agonist, inhibits icilin-induced wet-dog shakes in rats and antagonizes glutamate release in the dorsal striatum.

Authors:  Jennifer L Werkheiser; Scott M Rawls; Alan Cowan
Journal:  Neuropharmacology       Date:  2006-12-05       Impact factor: 5.250

4.  The adrenergic receptor agonist, clonidine, potentiates the anti-parkinsonian action of the selective kappa-opioid receptor agonist, enadoline, in the monoamine-depleted rat.

Authors:  M P Hill; J M Brotchie
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

Review 5.  Dynorphin and the pathophysiology of drug addiction.

Authors:  T S Shippenberg; A Zapata; V I Chefer
Journal:  Pharmacol Ther       Date:  2007-07-24       Impact factor: 12.310

6.  KOR Control over Addiction Processing: An Exploration of the Mesolimbic Dopamine Pathway.

Authors:  Paige M Estave; Mary B Spodnick; Anushree N Karkhanis
Journal:  Handb Exp Pharmacol       Date:  2022
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.